...
首页> 外文期刊>International braz j urol >Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma
【24h】

Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma

机译:透明细胞肾细胞癌中各种潜在预后标志物和存活数据的分析

获取原文
           

摘要

Purpose Clear cell renal cell cancers frequently harbor Von Hippel-Lindau gene mutations, leading to stabilization of the hypoxia-inducible factors (HIFs) and their target genes. In this study, we investigated the relationship between vascular endothelial growth factor (VEGF), HIF-1α, HIF-2α, p53 positivity, microvessel density, and Ki-67 rates with prognostic histopathologic factors (Fuhrman nuclear grade, stage, and sarcomatoid differentiation) and survival in clear cell renal cell carcinomas. Material and Methods Seventy-two nephrectomy specimens diagnosed as clear cell renal cell carcinoma between 2000 and 2012 were reevaluated. Immunohistochemically VEGF, HIF-1α, HIF-2α, p53, CD34 (for microvessel density evaluation), and Ki-67 antibodies were applied to the tumor areas. The relationships of these antibodies with prognostic factors and survival rates were evaluated with statistical analyses. Results Mean survival time was 105.6 months in patients with ccRCC. Patients with high expression of VEGF, HIF-1α and HIF-2α positivity, a high Ki-67 proliferation index, and a high microvessel density evaluation score had a shorter survival time (p<0.05). Conclusions Our findings supported that with the use of these immunohistochemical markers, prognosis of renal cell carcinoma may be predicted at the first step of patient management. New treatment modalities targeted to HIF-1α and HIF-2α might be planned as well as VEGF-targeted therapies in the management of clear cell renal cell carcinomas.
机译:目的透明细胞肾细胞癌经常含有von河ppel-lindau基因突变,导致缺氧诱导因子(HIF)及其靶基因的稳定性。在这项研究中,我们研究了血管内皮生长因子(VEGF),HIF-1α,HIF-2α,P53阳性,微血管密度和KI-67率与预后组神病理因子(FUHRMAN核级,阶段和SARCAMATOID分化的关系)和在透明细胞肾细胞癌中存活。材料和方法诊断为2000和2012之间被诊断为透明细胞肾细胞癌的七十二个肾切除术标本重新评估。免疫组织化学VEGF,HIF-1α,HIF-2α,P53,CD34(用于微血管密度评估)和KI-67抗体施用于肿瘤区域。通过统计分析评估这些抗体具有预后因子和存活率的关系。结果平均CCRCC患者的存活时间为105.6个月。 VEGF,HIF-1α和HIF-2α阳性高表达的患者,高KI-67增殖指数和高微血管密度评估评分的存活时间较短(P <0.05)。结论我们的调查结果支持,通过使用这些免疫组织化学标志物,可以在患者管理的第一步预测肾细胞癌的预后。靶向HIF-1α和HIF-2α的新治疗方式可以规划,以及在透明细胞肾细胞癌的管理中的VEGF靶向疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号